Here are relevant reports on : parkinsons-disease-market
-
Incontinence and Ostomy Care Market by Procedure (Ileostomy, Urostomy, Colostomy), Disease (Cancer, Crohn's Disease, Diarrhea), Product (Adsorbent, Deodorizer, Ostomy Bag, Skin Barrier), Application (Protection, Cleansing) Global Forecasts to 2019
The global incontinence and ostomy care market is estimated to grow at a high rate from 2014 to 2019. The key drivers propelling the growth of global incontinence and ostomy care market include global rise in population of obese and geriatric individuals, development of innovative and personalized products offering greater patient comfort, rising awareness and acceptance related to ostomy care products, and increasing prevalence of target diseases.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecast to 2026
The global prostate health market growth is primed to transition from USD 31.8 billion in 2021 to USD 48.9 billion by 2026, showcasing a strong CAGR of 9.0%. Growth in this market is primarily driven by the increasing prevalence of benign prostatic hyperplasia, increasing obesity, investments, funds, and grants for research in prostate health, an increase in the prevalence of prostate cancer, a surge in demand for hormone therapy drugs, emerging therapies for prostate cancer, and an increasing incidence of prostatitis.
- Published: December 2021
- Price: $ 4950
- TOC Available:
-
Asia Pacific Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral) - Forecast to 2030
The Asia Pacific Vaccines market, valued at USD 9.46 billion in 2024, stood at USD 9.89 billion in 2025 and is projected to advance at a resilient CAGR of 9.0% from 2025 to 2030, culminating in a forecasted valuation of USD14.57 billion by the end of the period. The market is expanding quickly, driven by a rise in vaccine development and commercialization, heightened infectious disease rates, and the extensive use of preventive vaccines.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Middle East & Africa In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Infectious Disease) - Forecast to 2031
The Middle East & Africa in vitro diagnostics (IVD) market, valued at USD 3.33 billion in 2025, stood at USD 3.49 billion in 2026 and is projected to advance at a resilient CAGR of 4.8% from 2026 to 2031, culminating in a forecasted valuation of USD 4.42 billion by the end of the period.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Slide Stainer Market by Product (Reagent (Stains, Probes, ABS), Equipment (Automated, Manual)), Technology (H&E, IHC, ISH, Cytology), Application (Disease Diagnosis (Cancer) Research), End User (Hospitals, Diagnostic Labs) - Global Forecast to 2027
Slide stainer market growth is primed to transition from $4.3 billion in 2022 to $5.9 billion by 2027, showcasing a strong CAGR of 6.8%. The growth in this market is driven by the increasing diagnosis of cancer, infectious, and other chronic diseases, expanding patient base and improving healthcare infrastructure.
- Published: September 2022
- Price: $ 4950
- TOC Available:
-
Sexually Transmitted Diseases Diagnostics Market by Disease Type (CT/NG, Gonorrhea, Syphilis, Genital Herpes, Hepatitis B, HIV/AIDS, HPV), End User (Laboratory, PoC) and Geography - Global Forecast to 2027
The STDs diagnostics market size is projected to reach $99,431.6 million by 2027 from $91,441.5 million in 2022, at a CAGR of 5.6% during the forecast period. Sexually transmitted diseases diagnostics market is driven by factors such as global prevalence of HIV, CT/NG, and other STDs and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, Region - Global Forecast to 2028
The global antibody drug conjugates market, valued at US$7.6 billion in 2022, stood at US$9.7 billion in 2023 and is projected to advance at a resilient CAGR of 15.2% from 2025 to 2028, culminating in a forecasted valuation of US$19.8 billion by the end of the period. Growth in the market can be attributed to various factors such as including the growing prevalence of cancer, and increasing R&D activities for the development of novel ADCs by key market players.
- Published: October 2023
- Price: $ 4950
- TOC Available:
-
Bioabsorbable Stents Market by Material (Polymer/Metal), Absorption Rate (Slow, Fast), Application (Coronary Artery Disease/CAD, Peripheral/PAD) & End User (Hospital, Cardiovascular Center) - Global Forecasts to 2022
The global bioresorbable stents market is projected to reach USD 417.2 Million by 2022, at a CAGR of 11.5%. Market growth of bioresorbable stents is attributed to the growing aging population susceptible to coronary and peripheral artery diseases, rising PCI procedures, increasing focus of companies on clinical trials of bioresorbable stents, increasing adoption of these stents by physicians and patients, and patients’ preference for minimally invasive therapies. However, factors such as the increasing product withdrawals due to severe complications of these stents may hamper market growth. The bioresorbable stents screening market is a niche market with the presence of several emerging players and few big players. Prominent players in the market include Abbott (U.S.), BIOTRONIK SE & Co. KG (Germany), REVA Medical, Inc. (U.S.), Elixir Medical Corporation (U.S.), and Kyoto Medical Planning Co., Ltd. (Japan).
- Published: August 2017
- Price: $ 4950
- TOC Available:
-
North America Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)-Forecast to 2030
The North America biomarkers Market, valued at US$23.35 billion in 2024, stood at US$25.13 billion in 2025 and is projected to advance at a resilient CAGR of 11.0% from 2025 to 2030, culminating in a forecasted valuation of US$45.25 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Latin America In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Disease) - Forecast to 2031
The Latin America in vitro diagnostics (IVD) market, valued at USD 5.48 billion in 2025, stood at USD 5.87 billion in 2026 and is projected to advance at a resilient CAGR of 6.7% from 2026 to 2031, culminating in a forecasted valuation of USD 8.13 billion by the end of the period. The increasing demand for diagnostic services, along with the growing need for routine and specialized testing, is driving the market. Investments in lab infrastructure, combined with the adoption of automated and standardized diagnostic procedures, contribute to increasing test volumes in both the public and private healthcare sectors.
- Published: May 2026
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
